GuruFocus Manual of Stocks™  |  Jun 06, 2023
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA
Usana Health Sciences Inc (NYSE:USNA)
[1]
Modestly Undervalued[5]$ 62.83
GF Score: 89/100Market Cap: $ 1,213 Mil
Industry: Consumer Defensive - Consumer Packaged Goods
IPO Date: 1993-04-22
Usana Health Sciences Inc is a US-based company that is principally engaged in developing, manufacturing, and selling science-based nutritional and personal-care products. The company operates through direct selling. It owns a number of product lines, such as Essentials, which contains core vitamin and mineral supplements; Optimizers, which includes targeted supplements for individuals' health and nutritional needs; Foods, which consists of low-glycemic meal replacement shakes, snack b... read more
Latest FY Operating Revenue by Business Segment
Business Segment Name2022Percentage
Direct-selling995.0499.64%
All Other3.560.36%
Financial Strength
Rank: 10 /10CurrentIndustry MedianHistorical Median
Cash-to-DebtNo Debt0.48No Debt
Equity-to-Asset0.750.530.68
Interest Coverage530.858.502547.76
Piotroski F-Score656
Profitability Rank
Rank: 9 /10CurrentIndustry MedianHistorical Median
Operating Margin %10.414.4514.52
Net Margin %6.702.859.88
ROE %15.586.0531.34
ROA %11.302.6521.43
ROC (Joel Greenblatt) %106.4910.09173.24
Growth Rank(* per share data)
Rank: 6 /1010-Yr5-Yr1-Yr
Revenue Growth %9.85.0-12.4
EBITDA Growth %8.83.1-28.7
Oprt. Income Growth %7.72.1-33.8
EPS w/o NRI Growth %7.77.0-37.3
FCF Growth %7.71.6-17.1
Book Value Growth %12.28.616.1
Momentum Rank
Rank: 9 /10CurrentIndustry MedianHistorical Median
5-Day RSI45.0149.96N/A
9-Day RSI42.9948.28N/A
14-Day RSI43.3447.99N/A
6-1M Momentum %21.61-1.96N/A
12-1M Momentum %-8.99-6.28N/A
Quarterly
Mar22Jun22Sep22Dec22Mar23
Revenue272.87264.47233.30227.96248.36
Net Income22.4719.1614.9312.8018.38
EPS1.151.000.780.660.95
Revenue YoY %-11.40-21.48-14.96-14.72-8.98
Net Income YoY %-26.62-49.90-45.38-37.03-18.19
EPS YoY %-20.69-46.52-42.65-35.92-17.39
Warning Signs
SEVEREOperating Margin %: Declined
Good Signs
GOODFinancial Strength: Strong Financial Strength
Insider Trades
InsiderPositionDateTradesCur. Shares
Brown JimPRESIDENT05/08/23-12202--
Neidig BrentCO & MAN. DIR. 05/05/23-2694--
Fleming John TurmanDirector05/05/23-12502,153
Nixon J ScottDirector04/28/23-2450924
Mulham David MulhamCHIEF SALES OFF04/28/23-113813,598
Fuller Gilbert ADirector04/28/23-404--
Winssinger Frederic JDirector04/27/23-20002,142
Guest KevinCHIEF EXECUTIVE03/07/23-52974,058
GF Value Rank
Rank: 7 /10CurrentIndustry MedianHistorical Median
PE Ratio18.5319.4015.75
Forward P/EN/A17.07N/A
PB Ratio2.661.414.70
PS Ratio1.250.931.59
P/FCF14.0419.0015.00
Shiller P/E13.0418.2024.64
PEG Ratio5.981.721.21
Valuation Analysis
Current% of Price
NCAV12.7320
Tangible Book21.0433
Graham Number40.0664
DCF (Earnings Based)50.6681
Price62.83
DCF (FCF Based)66.96107
GF Value78.42125
Median PS Value82.59131
EPV140.76224
Dividend & Ownership
Dividend Yield (TTM) %N/A
Dividend Yield (Forward) %N/A
Dividend Payout RatioN/A
Dividend Growth (5Y) %N/A
Yield on Cost (5Y) %N/A
Continuous Div. sinceN/A
Insider Ownership %5.93
Institution Ownership %36.45
As of 06-06-2023
* All financial numbers are in millions except for per share data, ratios and percentage change. "Neg. E" means negative equity.
20132014201520162017201820192020202120222023Performance
%GainSP500
1W0.871.87
1M-6.323.73
3M2.416.23
6M13.959.60
YTD18.2312.35
1Y-16.025.70
3Y-9.8611.94
5Y-11.8810.93
10Y6.5112.20
136.25
59.91
16.44
642552
321276
2013201420152016201720182019202020212022CurrentKey Data
45.7159.0988.0674.1375.60136.25118.9791.20106.45102.9476.58Highest Stock Price
16.4428.8148.9747.4154.2570.7558.9245.7877.9548.6648.61Lowest Stock Price
1,0501,2961,5951,4981,7792,7751,7011,6221,9631,0221,213Market Cap
28.427.426.425.024.724.622.821.320.319.319.3Shares Outstanding-Diluted
13.5918.3217.7915.3429.2722.9917.8113.1617.6614.8218.53PE Ratio
4.035.635.684.614.907.094.843.674.972.352.66PB Ratio
1.491.781.831.521.752.441.691.441.741.031.25PS Ratio
7.199.519.528.6710.1611.988.506.568.975.687.31EV-to-EBITDA
2013201420152016201720182019202020212022TTMPer Share Data
25.2828.8734.8540.1742.3948.2646.4953.3858.3251.7150.54Revenue per Share
2.782.803.593.992.535.124.415.865.733.593.39Earnings per Share
3.203.103.334.164.475.714.836.845.334.844.48Free Cash Flow per Share
----------------------Dividends per Share
7.206.789.0211.2012.9314.5314.1018.7017.8920.0321.04Tangible Book per Share
35.7140.1448.1755.5258.5069.8371.4784.2295.2184.4882.59Median PS Value
21.2220.6726.9831.7127.1340.9237.4049.6648.0340.2240.06Graham Number
2013201420152016201720182019202020212022TTMIncome Statement
718.18790.47918.501,0061,0471,1891,0611,1351,186998.60974.09Revenue
590.74649.68758.82825.89867.86988.54873.40925.53968.57804.71783.07Gross Profit
82.2682.1982.6182.0982.8783.1282.3381.5781.6380.5880.39Gross Margin %
474.03533.58617.16687.27735.36800.19727.21749.04798.37697.10681.68Total Operating Expense
116.71116.10141.66138.62132.50188.35146.19176.49170.19107.61101.39Operating Income
16.2514.6915.4213.7812.6515.8413.7815.5514.3410.7810.41Operating Margin %
79.0276.6494.67100.0462.54126.22100.53124.66116.5169.3565.26Net Income
11.009.6910.319.945.9710.619.4810.999.826.946.70Net Margin %
116.58115.78142.60139.00134.69191.55150.56178.46170.70108.81104.03EBIT
125.63124.59152.58152.48150.80208.39173.57200.96192.89130.22125.05EBITDA
35.4331.2437.0533.0118.1733.4727.0631.4327.8516.7215.58ROE %
24.8621.3224.4722.3812.6323.5118.7721.5319.1211.8111.30ROA %
2013201420152016201720182019202020212022Mar23Balance Sheet
145.99111.13143.21175.77247.13277.87234.83311.92239.83288.42295.45Cash & Equivalents & MS
229.05190.93244.26277.86340.16392.34329.28425.29365.12384.38395.88Total Current Assets
368.47350.58423.24470.64519.27554.46516.93640.89577.74596.55605.53Total Assets
------------8.328.627.086.89--Short-Term Debt & CLO
95.87108.71131.41138.49141.18148.69136.10168.07160.79143.83130.22Total Current Liabilities
----------------------Long-Term Debt & CLO
107.95120.42142.39145.36156.06163.32165.22199.24182.62162.08150.18Total Liabilities
260.52230.16280.85325.29363.21391.15351.71441.65395.12434.47455.35Total Stockholders Equity
260.52230.16280.85325.29363.21391.15351.71441.65395.12434.47455.35Total Equity
2013201420152016201720182019202020212022TTMCashflow Statement
98.89105.19111.47136.89123.77152.12126.73160.40121.23103.9097.03Cash Flow from Operations
-21.59-16.27-25.12-31.88-12.90-69.0047.49-33.96-14.19-12.37-13.96Cash Flow from Investing
-10.17-113.02-49.16-64.86-50.32-105.28-152.05-59.44-181.41-30.09-13.69Cash Flow from Financing
66.50-26.2232.0832.2271.58-33.3020.4578.25-72.2847.6756.79Net Change in Cash
137.34111.13143.21178.95250.54217.23237.69315.94243.65291.32298.37Ending Cash Position
-8.05-20.42-23.73-32.70-13.22-11.43-16.57-15.09-12.76-10.40-10.72Capital Expenditure
90.8484.7687.74104.19110.55140.69110.16145.31108.4693.5086.32Free Cash Flow
Competitor(* Up to 5 competitors are listed here. See full competitors list in the Competitive Comparison section below)
TickerCompanyMarket Cap
($M)
PE RatioGF Score
/100
Financial
Strength /10
Profitability
Rank /10
GF Value
Rank /10
Growth
Rank /10
Momentum
Rank /10
NYSE:UTZUtz Brands Inc1,305160.905843509
NYSE:USNAUsana Health Sciences Inc1,21318.5389109769
NYSE:HLFHerbalife Ltd1,2124.807649274
NYSE:BRCCBRC Inc1,137At Loss1851000
NAS:HAINThe Hain Celestial Group Inc1,082At Loss7056445
GuruFocus Manual of Stocks™  |  Jun 06, 2023
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA

Financial Strength[2] (Quarterly data, as of Mar. 2023) : Good (10/10)


Cash-to-Debt : No Debt

Cash-to-Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. A high ratio indicates that a company is better able to pay back its debt, and is thus able to take on more debt if necessary.


Equity-to-Asset : 0.75

Equity-to-Asset ratio is calculated as total stockholders equity divided by its total assets. Equity-to-Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity-to-Asset ratio (more leveraged) may have higher ROE % because of the leverage.


Debt-to-Equity : 0.00

A high Debt-to-Equity ratio generally means that a company has been aggressive in financing its growth with debt.


Piotroski F-Score : 6

The Piotroski F-Score is used to determine the strength of a firm's financial position, with 9 being the best and 0 being the worst.

0
1
2
3
4
5
6
7
8
9


WACC : 8.19% vs ROIC : 18.92%

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business.


Dividend Yield : 0.00%

Dividend yield is a way to measure how much cash flow you are getting for each dollar invested in an equity position.

GuruFocus Manual of Stocks™  |  Jun 06, 2023
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA

Profitability[3] (Annual data, as of Dec. 2022) : Good (9/10)

0
1
2
3
4
5
6
7
8
9

Revenue : $248 Mil vs Net Income : $18 Mil

Revenue is the amount of money that a company actually receives during a specific period, including discounts and deductions for returned merchandise. Net Income is a company's total profit. Net income is calculated by taking revenues and adjusting for the cost of doing business, depreciation, interest, taxes and other expenses.


Cash & Equivalents : $295 Mil vs Long-Term Debt* : $0 Mil

Cash & equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash. Long-Term Debt* consists of loans and obligations lasting over one year.


Operating Margin % : 10.81%

Operating margin % measures how much profit a company makes on a dollar of sales. Operating Margin % is calculated as Operating Income divided by Revenue.


EPS without NRI : $0.95

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock. In calculating earnings per share without non-recurring items, the dividends of preferred stocks and Non Operating Income need to subtracted from the total net income first.


Dividends per Share : $0.00

Dividends per Share is the amount of dividends that the shareholders of a company receive on a per-share basis. It is calculated using the total dividends paid out to shareholders over one fiscal year and the number of shares outstanding.


Free Cash Flow per Share : $0.56

Free Cash flow per Share is the amount of Free cash flow per outstanding share of the company's stock.

GuruFocus Manual of Stocks™  |  Jun 06, 2023
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA

Valuation (Quarterly data, as of Mar. 2023)

These valuation metrics should give you a sense of reasonable prices, but be careful with them. Always seek to understand why a valuation is changing over time.


Valuation Chart (Current stock price : $62.83)


PE Ratio without NRI : 18.55

The price-to-earnings ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.


PB Ratio : 2.67

The price-to-book ratio measures the valuation of the stock relative to the underlying asset of the company.


PS Ratio : 1.24

The price-to-sales ratio is a valuation ratio that compares a company’s stock price to its revenues. The price-to-sales ratio is an indicator of the value placed on each dollar of a company’s sales or revenues.


Price-to-Free-Cash-Flow : 14.04

Price-to-free-cash-flow is very similar to the valuation metric of price-to-operating-cash-flow but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures from a company's total operating cash flow, thereby reflecting the actual cash flow available to fund non-asset-related growth.


EV-to-EBIT : 8.83

Enterprise value of a company divided by its trailing 12 months earnings before interest and taxes (EBIT).

GuruFocus Manual of Stocks™  |  Jun 06, 2023
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA

Valuation Bands

In these charts the 10-year valuation bands of the price-to-earnings ratio (PE Ratio), price-to-book ratio (PB Ratio), price-to-sales ratio (PS Ratio) and price-to-operating-cash-flow ratio (POCF) are drawn together with the historical stock prices. For example, the upper line of the PE band is where the stock price would have been if it were always traded at the maximum PE ratio of the past 10 years. The lower line of the PE band is where the stock price would have been if it were always traded at the lowest PE ratio of the past 10 years. It is always better if the stock price is close to the lower line, which indicates a lower valuation.


Historical Price and PE Band


Historical Price and PS Band


Historical Price and PB Band


Historical Price and Price-to-Operating-Cash-Flow (POCF) Band

GuruFocus Manual of Stocks™  |  Jun 06, 2023
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA

Warning Signs

GuruFocus conducted a thorough checkup using a checklist of 32 items that cover the areas of financial strength, profitability, growth, and valuation of each company. The purpose of Warning Signs is to warn you that the company may have red flags in certain areas, helping to avoid overlooking them. These warning signs do not necessarily mean you should not invest in the stock. But you should be aware of them before you invest.


Severe Warning Signs

Operating Margin % : Declined

Usana Health Sciences Inc operating margin has been in a 5-year decline. The average rate of decline per year is -2.8%.

Good Signs

Financial Strength : Strong Financial Strength

Usana Health Sciences Inc shows strong financial strength.

Altman Z-Score : Strong

Altman Z-score of 8.43 is strong.

Beneish M-Score : Unlikely manipulator

Beneish M-Score -2.78 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

Interest Coverage : Comfortable

Usana Health Sciences Inc has no debt.

Medium Warning Signs

Revenue per Share : Declined

Usana Health Sciences Inc revenue per share is in decline over the past 12 months.

PS Ratio : Close to 1-year high

Usana Health Sciences Inc stock PS Ratio (=1.23) is close to 1-year high of 1.36

Insider Sell : Insider Selling

There were 7 insider selling transactions and no insider buying over the past 3 months. 22,138 shares were sold.
GuruFocus Manual of Stocks™  |  Jun 06, 2023
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA

Competitive Comparison


5 Year Price Change Comparison



Financial Strength

CompanyFinancial StrengthCash-to-DebtEquity-to-AssetDebt-to-EquityInterest CoveragePiotroski F-ScoreAltman Z-ScoreBeneish M-ScoreWACC %ROIC %
SHSE:603288Foshan Haitian Flavouring and Food Co Ltd10/1087.560.810.01424.93431.02-2.005.0554.80
NYSE:USNAUsana Health Sciences Inc10/10No Debt0.750.00530.8568.43-2.788.1918.92
NAS:JBSSJohn B Sanfilippo & Son Inc8/100.010.660.1437.1259.27-2.741.1018.48
OTCPK:MALGMicroalliance Group Inc8/109.150.960.01N/AN/A274.43-2.2132.0934.42
NSE:NESTLEINDNestle India Ltd8/104.510.270.1122.97722.72-2.607.0042.67
XPAR:BNDanone SA6/100.330.400.7911.0962.11-2.573.144.94
NYSE:BRCCBRC Inc5/100.310.103.490.00N/A3.83-0.830.00-61.18
NYSE:GISGeneral Mills Inc5/100.050.331.138.2373.18-2.594.038.47
MEX:BIMBOAGrupo Bimbo SAB de CV5/100.060.331.105.8272.96-2.567.746.55
NAS:SOVOSovos Brands Inc5/100.310.421.022.08N/A2.52-2.467.115.37
NAS:HAINThe Hain Celestial Group Inc5/100.050.440.942.1751.78-2.244.262.93
NAS:KHCThe Kraft Heinz Co5/100.040.540.415.1771.12-2.306.004.33
NAS:WESTWestrock Coffee Co5/100.090.370.940.59N/A1.69-1.800.003.46
NYSE:BGSB&G Foods Inc4/100.020.232.731.5351.41-2.452.877.02
NYSE:HLFHerbalife Ltd4/100.16-0.46-2.333.0952.11-2.498.3317.37
SHSE:600887Inner Mongolia Yili Industrial Group Co Ltd4/100.760.361.096.8852.70-2.648.199.54
XSWX:NESNNestle SA4/100.120.311.2912.8643.62-2.563.6310.24
NYSE:UTZUtz Brands Inc4/100.060.251.460.5461.02-2.646.19-0.13
SZSE:300999Yihai Kerry Arawana Holdings Co Ltd4/100.610.391.291.6062.57-2.476.691.75
NAS:BYNDBeyond Meat Inc2/100.22-0.26-4.670.002-0.80-5.487.80-43.46
GuruFocus Manual of Stocks™  |  Jun 06, 2023
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA

Competitive Comparison - Cont.


Profitability

CompanyProfitability RankOperating
Margin %
Net Margin %ROE %ROA %Price-to-Free-Cash-FlowROC (Joel Greenblatt) %3-Year Revenue Growth %3-Year EBITDA Growth %3-Year EPS w/o NRI Growth %
SHSE:603288Foshan Haitian Flavouring and Food Co Ltd10/1024.9523.9723.7318.4060.90139.479.606.805.70
NYSE:HLFHerbalife Ltd9/109.034.93Neg. E9.169.8871.1114.9011.3013.70
NSE:NESTLEINDNestle India Ltd9/1020.3014.35110.5629.4496.23109.0610.906.306.70
NYSE:USNAUsana Health Sciences Inc9/1010.416.7015.5811.3014.04106.493.60-3.90-6.60
XPAR:BNDanone SA8/1012.353.475.362.0917.1231.063.60-4.40-20.50
NYSE:GISGeneral Mills Inc8/1015.7614.0427.328.9919.89101.923.608.4015.10
MEX:BIMBOAGrupo Bimbo SAB de CV8/1010.475.4415.804.7558.7222.018.0022.1042.00
SHSE:600887Inner Mongolia Yili Industrial Group Co Ltd8/108.917.5919.077.4025.1933.588.9013.408.80
NAS:JBSSJohn B Sanfilippo & Son Inc8/108.806.4123.9314.8216.6328.042.7011.7015.80
XSWX:NESNNestle SA8/1016.949.7819.936.7544.8042.743.40-4.50-7.30
NYSE:BGSB&G Foods Inc7/109.85-1.48-3.57-0.8230.4110.396.30-11.800.00
NAS:KHCThe Kraft Heinz Co7/1017.409.004.962.6530.9859.691.90-1.406.50
NAS:HAINThe Hain Celestial Group Inc6/104.43-5.25-8.80-3.940.00-11.980.10118.600.00
NAS:BYNDBeyond Meat Inc3/10-71.96-80.830.00-28.470.00-46.26-2.20-446.00-170.70
NAS:SOVOSovos Brands Inc3/106.89-5.39-10.04-4.2443.54-20.9029.80-66.40-23.80
NYSE:UTZUtz Brands Inc3/101.830.571.160.290.004.968.50-0.9074.10
SZSE:300999Yihai Kerry Arawana Holdings Co Ltd3/101.451.434.251.670.007.7011.00-16.90-20.40
NAS:WESTWestrock Coffee Co2/102.21-6.16-25.95-7.640.00-8.420.000.000.00
NYSE:BRCCBRC Inc1/10-21.67-7.77-179.98-11.410.00-101.2746.600.00-348.10
OTCPK:MALGMicroalliance Group Inc1/1058.0342.9033.8231.15202.0048.230.000.000.00

Valuation

CompanyPE RatioPB RatioPS RatioPrice-to-Intrinsic-Value-Projected-FCFPrice-to-Intrinsic-Value-DCF (Earnings Based)Price-to-Median-PS-ValuePrice-to-Peter-Lynch-Fair-ValuePrice-to-Graham-NumberEarnings Yield (Joel Greenblatt) %Forward Rate of Return (Yacktman) %
NYSE:BGSB&G Foods IncAt Loss1.110.440.650.000.360.000.003.403.86
NYSE:BRCCBRC IncAt Loss13.100.910.000.000.000.000.00-8.190.00
NAS:BYNDBeyond Meat IncAt Loss0.001.810.000.000.000.000.00-18.450.00
NAS:SOVOSovos Brands IncAt Loss3.872.060.000.000.000.000.00-1.320.00
NAS:HAINThe Hain Celestial Group IncAt Loss1.070.600.810.000.360.000.00-4.1924.27
NAS:WESTWestrock Coffee CoAt Loss80.000.830.000.000.000.000.00-1.760.00
NYSE:HLFHerbalife Ltd4.800.000.230.290.360.200.470.0013.5134.47
NYSE:GISGeneral Mills Inc18.104.822.551.521.381.273.310.005.7110.33
NYSE:USNAUsana Health Sciences Inc18.532.661.250.821.240.760.001.5711.389.83
NAS:KHCThe Kraft Heinz Co19.280.941.720.760.000.000.000.005.992.30
SHSE:600887Inner Mongolia Yili Industrial Group Co Ltd19.783.511.511.930.900.771.781.946.1813.32
NAS:JBSSJohn B Sanfilippo & Son Inc21.344.761.331.911.061.581.962.206.4514.50
MEX:BIMBOAGrupo Bimbo SAB de CV25.313.741.371.341.191.641.350.005.7023.67
XSWX:NESNNestle SA32.156.913.132.340.001.110.000.003.715.80
XPAR:BNDanone SA37.812.001.301.030.000.790.000.004.721.67
SHSE:603288Foshan Haitian Flavouring and Food Co Ltd45.158.1810.822.891.430.003.914.112.8813.29
SZSE:300999Yihai Kerry Arawana Holdings Co Ltd57.102.410.800.000.000.000.002.822.500.00
OTCPK:MALGMicroalliance Group Inc77.6920.2031.5620.200.000.000.008.422.170.00
NSE:NESTLEINDNestle India Ltd83.1385.6011.937.834.521.3611.0818.321.7210.43
NYSE:UTZUtz Brands Inc160.901.880.950.000.000.000.000.000.990.00
GuruFocus Manual of Stocks™  |  Jun 06, 2023
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA

Peter Lynch Chart[4]

GuruFocus Manual of Stocks™  |  Jun 06, 2023
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA

Per Share Data


Per Share Data

Dec07
Dec08
Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
TTM Fiscal Period
12.30
13.27
14.16
16.24
18.68
21.74
25.28
28.87
34.85
40.17
42.39
48.26
46.49
53.38
58.32
51.71
50.54
Revenue per Share
2.21
1.67
1.90
2.41
2.76
3.59
4.42
4.55
5.79
6.09
6.10
8.46
7.61
9.45
9.48
6.74
6.49
EBITDA per Share
2.06
1.46
1.67
2.16
2.49
3.30
4.10
4.23
5.41
5.55
5.45
7.77
6.60
8.40
8.39
5.64
5.40
EBIT per Share
1.32
0.93
1.09
1.43
1.63
2.23
2.78
2.80
3.59
3.99
2.53
5.12
4.41
5.86
5.73
3.59
3.39
Earnings per Share (Diluted)
1.34
0.93
1.09
1.43
1.63
2.23
2.78
2.80
3.59
3.99
2.53
5.12
4.41
5.86
5.73
3.59
3.39
EPS without NRI
1.30
0.90
0.38
1.43
1.60
2.72
3.24
3.97
3.84
4.16
3.65
4.84
4.30
6.11
4.80
4.07
3.69
Owner Earnings per Share (TTM)
0.90
0.93
0.92
1.94
1.91
2.83
3.20
3.10
3.33
4.16
4.47
5.71
4.83
6.84
5.33
4.84
4.48
Free Cash Flow per Share
1.66
1.42
1.05
2.07
2.25
3.11
3.48
3.84
4.23
5.47
5.01
6.17
5.55
7.55
5.96
5.38
5.04
Operating Cash Flow per Share
0.39
0.43
0.45
0.79
1.69
2.56
5.26
4.40
5.73
7.18
10.29
11.79
10.84
14.83
12.37
15.02
15.31
Cash per Share
1.18
1.04
2.43
4.74
5.82
6.71
9.38
9.11
11.25
13.29
15.12
16.60
16.24
20.99
20.38
22.62
23.60
Book Value per Share
1.01
0.85
2.24
2.86
3.80
4.54
7.20
6.78
9.02
11.20
12.93
14.53
14.10
18.70
17.89
20.03
21.04
Tangible Book per Share
0.85
1.14
0.23
--
--
--
--
--
--
--
--
--
0.38
0.41
0.37
0.36
-- Total Debt per Share
18.54
17.12
15.95
21.73
15.19
16.47
37.79
51.30
63.88
61.20
74.05
118
78.55
77.10
101
53.20
62.83
Month End Stock Price

Ratios

Dec07
Dec08
Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
TTM Fiscal Period
91.70
84.98
63.19
41.59
31.81
36.96
35.43
31.24
37.05
33.01
18.17
33.47
27.06
31.43
27.85
16.72
15.58
ROE %
5.83
5.15
9.62
9.08
12.19
15.09
8.79
5.55
6.52
7.16
3.71
4.72
5.59
8.56
5.60
7.11
5.86
ROE % Adjusted to Book Value
43.34
25.85
27.28
27.90
22.64
25.96
24.86
21.32
24.47
22.38
12.63
23.51
18.77
21.53
19.12
11.81
11.30
ROA %
104
101
70.77
58.41
50.46
55.56
48.55
41.29
47.76
40.07
21.38
38.65
31.04
35.68
31.47
18.96
17.67
Return-on-Tangible-Equity
45.83
27.18
28.60
34.58
30.72
33.94
30.67
25.56
28.72
25.42
14.11
25.96
20.59
23.45
20.76
12.89
12.36
Return-on-Tangible-Asset
172
86.59
90.50
120
131
161
193
178
179
147
132
197
161
182
169
109
106
ROC (Joel Greenblatt) %
110
68.79
68.33
60.19
46.82
51.64
49.70
45.01
53.44
44.55
37.93
48.87
38.28
41.81
38.37
25.02
23.67
ROCE %
17.79
3.34
1.75
5.56
4.94
17.89
18.57
12.77
14.99
11.42
-1.71
12.74
4.26
8.54
13.52
-6.16
-6.30
5-Year RORE %
19.90
-131
-96.65
19.51
19.47
144
58.98
-7.11
52.19
24.21
217
-1,326
-181
51.31
404
324
167
1-Year ROIIC %
62.07
34.24
35.21
36.50
30.14
35.40
38.87
33.49
35.98
34.49
20.96
43.95
33.98
38.65
33.75
20.45
18.92
ROIC %
4.32
3.04
8.27
8.26
9.37
7.04
10.65
15.50
8.29
8.92
2.51
6.55
4.78
6.67
7.95
8.49
8.19
WACC %
--
2.51
2.90
1.34
--
--
--
--
--
--
--
--
0.79
5.99
0.73
2.75
2.39
Effective Interest Rate on Debt %
79.23
79.28
79.45
81.55
82.53
82.15
82.26
82.19
82.61
82.09
82.87
83.12
82.33
81.57
81.63
80.58
80.39
Gross Margin %
16.71
11.19
11.62
13.18
13.28
15.13
16.25
14.69
15.42
13.78
12.65
15.84
13.78
15.55
14.34
10.78
10.41
Operating Margin %
10.71
6.98
7.68
8.82
8.72
10.24
11.00
9.69
10.31
9.94
5.97
10.61
9.48
10.99
9.82
6.94
6.70
Net Margin %
17.97
12.54
13.42
14.85
14.77
16.54
17.49
15.76
16.61
15.16
14.40
17.52
16.36
17.71
16.26
13.04
12.84
EBITDA Margin %
7.32
6.97
6.49
11.96
10.22
13.01
12.65
10.72
9.55
10.36
10.56
11.83
10.38
12.81
9.14
9.36
8.86
FCF Margin %
0.73
1.10
0.09
--
--
--
--
--
--
--
--
--
0.02
0.02
0.02
0.02
-- Debt-to-Equity
0.35
0.26
0.60
0.71
0.71
0.69
0.71
0.66
0.66
0.69
0.70
0.71
0.68
0.69
0.68
0.73
0.75
Equity-to-Asset
0.26
0.29
0.06
--
--
--
--
--
--
--
--
--
0.02
0.01
0.01
0.01
-- Debt-to-Asset
0.65
0.74
0.40
0.29
0.29
0.31
0.29
0.34
0.34
0.31
0.30
0.30
0.32
0.31
0.32
0.27
0.25
Liabilities-to-Assets
321
294
282
258
214
208
186
181
196
185
175
184
163
160
159
137
136
Gross-Profit-to-Asset %
4.05
3.70
3.55
3.16
2.60
2.54
2.26
2.20
2.37
2.25
2.12
2.22
1.98
1.96
1.95
1.70
1.69
Asset Turnover
--
2.71
2.49
2.30
2.34
--
--
--
--
--
--
--
--
--
--
--
-- Days Sales Outstanding
38.11
30.78
25.79
23.42
25.84
23.63
23.69
22.40
20.37
19.33
21.19
19.76
21.87
26.81
26.55
23.11
20.39
Days Payable
87.05
88.95
101
114
128
116
120
120
127
133
130
132
147
139
158
156
145
Days Inventory
48.94
60.88
77.58
93.25
104
92.12
96.21
97.49
107
113
109
112
125
112
131
133
125
Cash Conversion Cycle
--
135
147
159
156
--
--
--
--
--
--
--
--
--
--
--
-- Receivables Turnover
4.19
4.10
3.62
3.19
2.86
3.15
3.04
3.04
2.87
2.75
2.81
2.77
2.49
2.63
2.31
2.34
2.51
Inventory Turnover
0.21
0.21
0.21
0.18
0.17
0.18
0.18
0.18
0.17
0.18
0.17
0.17
0.18
0.18
0.18
0.19
0.20
COGS-to-Revenue
0.05
0.05
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.07
0.06
0.06
0.07
0.07
0.08
0.08
0.08
Inventory-to-Revenue
0.06
0.04
0.01
0.01
0.02
0.01
0.01
0.03
0.03
0.03
0.01
0.01
0.02
0.01
0.01
0.01
0.01
Capex-to-Revenue
0.37
0.34
0.08
0.06
0.14
0.09
0.07
0.18
0.17
0.24
0.10
0.06
0.11
0.09
0.08
0.10
0.11
Capex-to-Operating-Income
0.46
0.35
0.13
0.06
0.15
0.09
0.08
0.19
0.21
0.24
0.11
0.08
0.13
0.09
0.11
0.10
0.11
Capex-to-Operating-Cash-Flow
* All financial numbers are in millions except for per share data, ratios and percentage change. When Return-on-Tangible-Equity displays Neg. E, it means the the tangible equity is negative. When ROE % or ROE % Adjusted to Book Value displays Neg. E, it means the the total shareholders equity is negative.
GuruFocus Manual of Stocks™  |  Jun 06, 2023
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA

Financial Statement

Income Statement

Dec07
Dec08
Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
TTM Fiscal Period
423
429
437
518
582
649
718
790
918
1,006
1,047
1,189
1,061
1,135
1,186
999
974
Revenue
87.89
88.88
89.80
95.48
102
116
127
141
160
180
179
201
188
209
218
194
191
Cost of Goods Sold
335
340
347
422
480
533
591
650
759
826
868
989
873
926
969
805
783
Gross Profit
79.23
79.28
79.45
81.55
82.53
82.15
82.26
82.19
82.61
82.09
82.87
83.12
82.33
81.57
81.63
80.58
80.39
Gross Margin %
261
292
296
354
403
435
474
534
617
687
735
800
727
749
798
697
682
Selling, General, & Admin. Expense
3.36
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
-- Research & Development
--
--
--
-0.00
--
0.00
--
--
--
--
--
--
0.00
--
--
--
-- Other Operating Expense
265
292
296
354
403
435
474
534
617
687
735
800
727
749
798
697
682
Total Operating Expense
70.70
48.00
50.79
68.22
77.26
98.18
117
116
142
139
133
188
146
176
170
108
101
Operating Income
16.71
11.19
11.62
13.18
13.28
15.13
16.25
14.69
15.42
13.78
12.65
15.84
13.78
15.55
14.34
10.78
10.41
Operating Margin %
--
0.25
0.08
0.17
0.19
0.25
0.46
0.50
1.12
1.48
2.19
4.43
4.71
2.54
2.52
3.79
4.83
  Interest Income
--
-0.79
-0.61
-0.09
-0.01
-0.02
-0.00
-0.13
-0.02
-0.44
-0.05
-0.04
-0.07
-0.51
-0.06
-0.19
-0.19
  Interest Expense
--
-0.54
-0.53
0.07
0.18
0.23
0.46
0.37
1.10
1.04
2.14
4.39
4.64
2.03
2.46
3.60
4.63
Net Interest Income
0.47
-1.13
0.71
0.58
0.04
0.02
-0.59
-0.82
-0.17
-1.11
-0.00
-1.23
-0.33
-0.57
-2.01
-2.59
-2.19
Other Income (Expense)
71.17
46.32
50.98
68.86
77.48
98.43
117
116
143
139
135
192
150
178
171
109
104
Pre-Tax Income
-25.24
-16.38
-17.42
-23.21
-26.73
-31.99
-37.56
-39.02
-47.92
-38.51
-72.11
-65.29
-49.97
-53.28
-54.14
-39.27
-38.57
Tax Provision
35.47
35.35
34.18
33.71
34.49
32.50
32.22
33.74
33.60
27.80
53.55
34.09
33.20
29.94
31.73
36.15
37.15
Tax Rate %
-0.61
0.00
--
--
0.00
--
--
--
--
--
0.00
0.00
-0.00
-0.00
--
--
-0.00
Other Net Income (Loss)
45.32
29.95
33.56
45.65
50.75
66.43
79.02
76.64
94.67
100
62.54
126
101
125
117
69.35
65.26
Net Income Including Noncontrolling Interests
45.93
29.95
33.56
45.65
50.75
66.43
79.02
76.64
94.67
100
62.54
126
101
125
117
69.35
65.26
  Net Income (Continuing Operations)
-0.61
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--   Net Income (Discontinued Operations)
45.32
29.95
33.56
45.65
50.75
66.43
79.02
76.64
94.67
100
62.54
126
101
125
117
69.35
65.26
Net Income
10.71
6.98
7.68
8.82
8.72
10.24
11.00
9.69
10.31
9.94
5.97
10.61
9.48
10.99
9.82
6.94
6.70
Net Margin %
1.36
0.94
1.10
1.47
1.65
2.29
2.89
2.90
3.72
4.14
2.57
5.24
4.44
5.89
5.78
3.60
3.40
EPS (Basic)
1.32
0.93
1.09
1.43
1.63
2.23
2.78
2.80
3.59
3.99
2.53
5.12
4.41
5.86
5.73
3.59
3.39
EPS (Diluted)
34.41
32.33
30.86
31.88
31.15
29.85
28.41
27.38
26.36
25.05
24.71
24.64
22.82
21.26
20.34
19.31
19.33
Shares Outstanding (Diluted Average)
70.70
47.11
51.59
68.96
77.49
98.45
117
116
143
139
135
192
151
178
171
109
104
EBIT
5.33
6.70
7.07
7.92
8.47
8.83
9.04
8.81
9.98
13.48
16.11
16.84
23.01
22.51
22.19
21.41
21.03
Depreciation, Depletion and Amortization
76.03
53.81
58.66
76.87
85.96
107
126
125
153
152
151
208
174
201
193
130
125
EBITDA
17.97
12.54
13.42
14.85
14.77
16.54
17.49
15.76
16.61
15.16
14.40
17.52
16.36
17.71
16.26
13.04
12.84
EBITDA Margin %
* All financial numbers are in millions except for per share data, ratios and percentage change.
GuruFocus Manual of Stocks™  |  Jun 06, 2023
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA

Financial Statement

Cashflow Statement

Dec07
Dec08
Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
TTM Fiscal Period
45.32
29.95
33.56
45.65
50.75
66.43
79.02
76.64
94.67
100
62.54
126
101
125
117
69.35
65.26
Net Income From Continuing Operations
5.33
6.70
7.07
7.92
8.47
8.83
9.04
8.81
9.98
13.48
16.11
16.84
23.01
22.51
22.19
21.41
21.03
Depreciation, Depletion and Amortization
2.68
-7.22
-1.12
-4.98
-3.21
1.37
-11.78
1.10
-23.07
-1.03
6.05
-23.10
12.99
-16.78
-10.50
21.88
24.04
  Change In Inventory
-2.56
-5.31
1.69
-5.22
4.02
-6.34
-8.47
-3.79
-2.05
-9.75
5.01
-1.63
7.19
-5.19
-2.33
-3.30
-6.64
  Change In Prepaid Assets
-3.14
0.69
-1.14
-1.98
1.50
-0.99
9.87
13.38
14.51
-1.34
3.04
-1.72
1.84
6.08
-4.57
-2.66
-0.75
  Change In Payables And Accrued Expense
6.15
17.34
-14.87
13.48
-0.38
12.58
20.25
15.07
20.94
22.53
-6.52
18.70
-30.80
16.46
-11.46
-9.07
-12.51
  Change In Other Working Capital
3.14
5.50
-15.45
1.30
1.94
6.62
9.87
25.76
10.33
10.41
7.59
-7.75
-8.79
0.56
-28.86
6.85
4.14
Change In Working Capital
-1.57
-2.44
-2.30
3.19
-1.60
4.11
0.81
-1.04
-2.57
-3.70
19.31
0.70
-3.64
-2.42
-2.97
-7.18
-7.29
Deferred Tax
--
7.69
8.93
10.41
10.55
10.21
7.62
9.81
11.08
16.54
15.48
14.96
15.54
14.39
14.30
13.33
13.77
Stock Based Compensation
--
--
--
--
--
--
--
--
--
--
2.73
-0.66
--
0.51
--
--
-- Asset Impairment Charge
5.00
-1.44
0.66
-2.36
-0.00
-3.40
-7.48
-14.79
-12.02
0.12
0.02
1.80
0.09
0.19
0.06
0.14
0.13
Cash Flow from Others
57.22
45.96
32.47
66.11
70.11
92.81
98.89
105
111
137
124
152
127
160
121
104
97.03
Cash Flow from Operations
-26.26
-16.06
-4.13
-4.19
-10.64
-8.43
-8.05
-20.42
-23.73
-32.70
-13.22
-11.43
-16.57
-15.09
-12.76
-10.40
-10.72
Purchase Of Property, Plant, Equipment
0.80
0.15
0.84
0.03
0.03
0.15
0.05
0.01
0.19
0.01
0.02
0.38
0.02
0.01
0.02
0.01
0.00
Sale Of Property, Plant, Equipment
--
--
--
-42.69
--
--
--
--
--
--
--
--
--
--
--
-6.53
-- Purchase Of Business
--
--
--
--
--
--
-8.64
-3.87
--
--
--
-86.40
-1.66
-21.09
-1.56
--
-1.27
Purchase Of Investment
--
--
--
--
--
--
--
12.51
--
--
--
23.60
65.48
1.94
--
4.56
-- Sale Of Investment
-0.54
0.71
0.09
--
0.00
-0.00
-4.94
-4.50
-1.58
0.80
0.30
4.85
0.23
0.28
0.12
0.00
-1.98
Cash From Other Investing Activities
-26.01
-15.21
-3.20
-46.85
-10.61
-8.28
-21.59
-16.27
-25.12
-31.88
-12.90
-69.00
47.49
-33.96
-14.19
-12.37
-13.96
Cash Flow from Investing
3.15
0.75
--
--
--
--
--
--
--
--
--
--
--
--
--
--
-- Issuance of Stock
-79.58
-39.87
-1.65
-17.03
-33.46
-68.29
-18.09
-139
-61.18
-64.61
-50.00
-105
-150
-57.03
-178
-25.38
-- Repurchase of Stock
28.00
85.02
57.02
69.30
--
1.85
--
30.00
--
73.70
3.50
--
5.00
60.00
--
11.00
1.00
  Issuance of Debt
--
-78.03
-85.01
-76.30
--
-1.85
--
-30.00
--
-73.70
-3.50
--
-5.00
-60.00
--
-11.00
-11.00
  Payments of Debt
28.00
6.99
-27.99
-7.00
--
--
--
--
--
--
--
--
--
--
--
--
-10.00
Net Issuance of Debt
2.53
2.37
0.14
14.45
0.09
3.75
7.92
25.80
12.02
-0.25
-0.32
0.10
-2.05
-2.41
-3.58
-4.71
-0.30
Other Financing
-45.90
-29.77
-29.50
-9.58
-33.37
-64.54
-10.17
-113
-49.16
-64.86
-50.32
-105
-152
-59.44
-181
-30.09
-13.69
Cash Flow from Financing
27.03
12.87
13.28
13.66
24.22
50.35
70.84
137
111
147
179
251
217
238
316
244
242
Beginning Cash Position
0.53
-0.57
0.61
0.89
0.00
0.50
-0.64
-2.12
-5.10
-7.93
11.03
-11.14
-1.72
11.25
2.09
-13.78
-12.58
  Effect of Exchange Rate Changes
-14.16
0.42
0.38
10.56
26.13
20.49
66.50
-26.22
32.08
32.22
71.58
-33.30
20.45
78.25
-72.28
47.67
56.79
Net Change in Cash
12.87
13.28
13.66
24.22
50.35
70.84
137
111
143
179
251
217
238
316
244
291
298
Ending Cash Position
-26.26
-16.06
-4.13
-4.19
-10.64
-8.43
-8.05
-20.42
-23.73
-32.70
-13.22
-11.43
-16.57
-15.09
-12.76
-10.40
-10.72
Capital Expenditure
30.96
29.90
28.34
61.92
59.47
84.37
90.84
84.76
87.74
104
111
141
110
145
108
93.50
86.32
Free Cash Flow
* All financial numbers are in millions except for per share data, ratios and percentage change.
GuruFocus Manual of Stocks™  |  Jun 06, 2023
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA

Financial Satement

Balance Sheet

Dec07
Dec08
Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
TTM Fiscal Period
12.87
13.28
13.66
24.22
50.35
70.84
137
111
143
176
247
214
235
312
240
288
295
  Cash And Cash Equivalents
--
--
--
--
--
--
8.64
--
--
--
--
63.54
--
--
--
--
--   Marketable Securities
12.87
13.28
13.66
24.22
50.35
70.84
146
111
143
176
247
278
235
312
240
288
295
Cash, Cash Equivalents, Marketable Securities
--
3.18
2.78
3.74
--
--
--
--
--
--
--
--
--
--
--
--
--   Accounts Receivable
6.86
3.76
0.51
3.11
5.66
8.24
13.60
11.03
11.78
17.04
13.46
14.03
8.76
7.42
7.16
7.21
--   Other Current Receivables
6.86
6.94
3.28
6.84
5.66
8.24
13.60
11.03
11.78
17.04
13.46
14.03
8.76
7.42
7.16
7.21
-- Total Receivables
5.73
7.06
6.79
9.37
9.67
9.23
13.82
15.13
22.53
26.19
20.74
19.50
15.88
28.33
30.28
21.78
20.61
  Inventories, Raw Materials & Components
5.83
5.41
5.00
5.79
6.92
7.70
8.15
7.55
8.70
9.46
8.46
14.49
12.11
9.96
9.59
4.29
2.99
  Inventories, Work In Process
7.88
11.40
13.97
18.92
20.38
19.55
25.27
22.58
34.89
29.17
33.72
47.96
40.92
51.94
58.45
41.03
40.90
  Inventories, Finished Goods
--
0.00
-0.00
--
--
--
-0.00
-0.00
--
--
--
--
--
0.00
--
--
-0.00
  Inventories, Other
19.44
23.88
25.76
34.08
36.97
36.48
47.24
45.25
66.12
64.81
62.92
81.95
68.91
90.22
98.32
67.09
64.49
Total Inventories
6.83
8.57
9.23
15.13
13.08
16.99
22.22
23.53
23.15
20.23
16.65
18.49
16.78
15.73
19.80
21.66
35.93
Other Current Assets
45.99
52.67
51.93
80.27
106
133
229
191
244
278
340
392
329
425
365
384
396
Total Current Assets
3.54
8.20
9.38
10.16
10.16
10.41
9.40
8.91
8.41
8.91
10.59
10.13
9.92
10.47
10.37
9.99
--   Land And Improvements
27.17
36.24
37.95
39.33
40.17
40.77
39.50
38.92
38.24
70.72
73.34
71.33
71.26
79.67
80.82
78.07
--   Buildings And Improvements
15.60
43.72
48.48
50.75
57.12
60.64
62.02
61.39
67.12
78.03
88.20
90.59
93.69
100
111
114
--   Machinery, Furniture, Equipment
15.87
1.46
0.68
0.22
1.42
1.57
2.69
14.86
33.04
7.10
4.17
2.45
11.49
11.07
5.50
6.08
--   Construction In Progress
26.35
3.87
4.48
5.40
6.32
7.42
8.30
11.46
12.19
12.30
12.74
13.10
13.40
15.24
15.21
14.39
96.80
  Other Gross PPE
88.52
93.48
101
106
115
121
122
136
159
177
189
188
200
217
223
223
96.80
Gross Property, Plant and Equipment
-36.46
-36.72
-43.71
-48.30
-54.44
-59.05
-62.72
-64.37
-71.03
-75.79
-86.20
-95.56
-105
-116
-122
-125
--   Accumulated Depreciation
52.06
56.76
57.24
57.57
60.75
61.75
59.18
71.16
87.98
101
103
92.03
95.23
100
102
97.77
96.80
Property, Plant and Equipment
5.69
5.69
5.69
57.55
60.38
59.98
60.57
58.89
55.70
51.06
52.57
48.63
46.48
48.16
48.11
49.80
49.38
Intangible Assets
5.69
5.69
5.69
16.93
17.74
17.89
18.24
17.94
17.43
16.72
17.42
16.82
16.64
17.37
17.67
17.37
17.41
  Goodwill
5.39
7.45
8.58
8.42
17.31
13.08
19.67
29.60
35.29
40.45
23.69
21.48
45.95
66.99
62.73
64.59
63.48
Other Long Term Assets
63.14
69.90
71.51
124
138
135
139
160
179
193
179
162
188
216
213
212
210
Total Long-Term Assets
109
123
123
204
244
267
368
351
423
471
519
554
517
641
578
597
606
Total Assets
8.11
6.88
5.81
6.45
7.95
7.04
9.50
7.78
10.04
9.04
11.79
9.95
12.53
18.20
13.51
11.05
10.51
  Accounts Payable
--
10.17
3.97
6.24
8.40
5.98
11.36
13.75
15.67
17.45
23.68
20.77
16.53
20.27
16.52
16.21
--   Total Tax Payable
--
--
--
-0.00
--
--
-0.00
--
--
--
--
--
0.00
--
--
--
--   Other Current Payables
10.14
11.21
8.51
14.40
--
--
--
1.81
6.86
2.22
--
--
--
--
--
--
--   Current Accrued Expense
18.25
28.26
18.29
27.08
16.36
13.02
20.87
23.34
32.58
28.71
35.47
30.72
29.06
38.46
30.03
27.26
10.51
Accounts Payable & Accrued Expense
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--   Short-Term Debt
--
--
--
--
--
--
--
--
--
--
--
--
8.32
8.62
7.08
6.89
--   Short-Term Capital Lease Obligation
--
--
--
--
--
--
--
--
--
--
--
--
8.32
8.62
7.08
6.89
-- Short-Term Debt & Capital Lease Obligation
4.30
6.59
7.39
11.77
10.07
15.60
16.06
15.72
17.64
21.46
17.00
15.06
13.85
15.95
19.64
20.88
--   Current Deferred Revenue
--
--
--
--
0.97
1.38
5.07
5.27
4.43
--
--
--
--
--
--
--
--   Current Deferred Taxes Liabilities
4.30
6.59
7.39
11.77
11.04
16.98
21.13
20.99
22.07
21.46
17.00
15.06
13.85
15.95
19.64
20.88
-- DeferredTaxAndRevenue
17.63
19.69
14.81
18.77
32.30
40.84
53.88
64.38
76.77
88.32
88.72
103
84.86
105
104
88.81
120
Other Current Liabilities
40.19
54.53
40.48
57.62
59.70
70.84
95.87
109
131
138
141
149
136
168
161
144
130
Total Current Liabilities
28.00
34.99
7.00
--
--
--
--
--
--
--
--
--
--
--
--
--
--   Long-Term Debt
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--   Long-Term Capital Lease Obligation
28.00
34.99
7.00
--
--
--
--
--
--
--
--
--
--
--
--
--
-- Long-Term Debt & Capital Lease Obligation
0.73
1.10
0.09
--
--
--
--
--
--
--
--
--
0.02
0.02
0.02
0.02
-- Debt-to-Equity
--
--
--
--
9.95
10.00
10.87
10.60
9.82
5.50
13.73
13.37
10.28
12.01
7.50
4.07
5.58
NonCurrent Deferred Liabilities
2.30
1.21
1.59
1.01
0.94
0.94
1.21
1.11
1.15
1.36
1.15
1.26
18.84
19.16
14.33
14.17
14.38
Other Long-Term Liabilities
30.31
36.20
8.59
1.01
10.89
10.94
12.08
11.72
10.97
6.86
14.88
14.63
29.12
31.16
21.83
18.24
19.96
Total Long-Term Liabilities
70.49
90.74
49.07
58.64
70.59
81.78
108
120
142
145
156
163
165
199
183
162
150
Total Liabilities
0.02
0.02
0.02
0.02
0.02
0.01
0.01
0.01
0.03
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
Common Stock
30.11
24.11
56.41
90.21
119
135
200
166
215
265
288
330
306
383
345
392
410
Retained Earnings
0.99
-0.38
1.52
3.72
5.84
6.94
5.79
2.13
-3.78
-11.65
-1.43
-10.39
-13.90
-3.63
0.46
-12.79
-11.04
Accumulated other comprehensive income (loss)
7.53
8.09
16.43
51.22
49.26
43.82
54.69
61.61
69.73
71.51
76.54
72.01
59.45
62.46
50.01
55.60
56.35
Additional Paid-In Capital
--
--
0.00
--
--
-0.00
--
-0.00
--
--
--
0.00
--
--
--
-0.00
-- Other Stockholders Equity
38.64
31.84
74.37
145
174
186
261
230
281
325
363
391
352
442
395
434
455
Total Stockholders Equity
38.64
31.84
74.37
145
174
186
261
230
281
325
363
391
352
442
395
434
455
Total Equity
0.35
0.26
0.60
0.71
0.71
0.69
0.71
0.66
0.66
0.69
0.70
0.71
0.68
0.69
0.68
0.73
0.75
Equity-to-Asset
* All financial numbers are in millions except for per share data, ratios and percentage change.
GuruFocus Manual of Stocks™  |  Jun 06, 2023
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA

Valuation Ratios

Valuation Ratios

Dec07
Dec08
Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
TTM Fiscal Period
14.10
18.51
14.70
15.20
9.32
7.40
13.59
18.32
17.79
15.34
29.27
22.99
17.81
13.16
17.66
14.82
18.53
PE Ratio
13.89
18.51
14.70
15.20
9.32
7.40
13.59
18.32
17.79
15.34
29.27
22.99
17.81
13.16
17.66
14.82
18.53
PE Ratio without NRI
14.27
19.00
41.86
15.21
9.48
6.06
11.67
12.91
16.63
14.72
20.28
24.35
18.26
12.61
21.07
13.08
17.03
Price-to-Owner-Earnings
15.73
16.51
6.57
4.58
2.61
2.45
4.03
5.63
5.68
4.61
4.90
7.09
4.84
3.67
4.97
2.35
2.66
PB Ratio
18.45
20.09
7.11
7.59
4.00
3.62
5.25
7.57
7.09
5.46
5.73
8.10
5.57
4.12
5.66
2.66
2.99
Price-to-Tangible-Book
20.60
18.51
17.37
11.19
7.96
5.83
11.82
16.57
19.19
14.71
16.55
20.62
16.27
11.28
18.98
10.99
14.04
Price-to-Free-Cash-Flow
11.15
12.04
15.16
10.48
6.75
5.30
10.86
13.35
15.11
11.20
14.78
19.07
14.14
10.22
16.98
9.89
12.45
Price-to-Operating-Cash-Flow
1.51
1.29
1.13
1.34
0.81
0.76
1.49
1.78
1.83
1.52
1.75
2.44
1.69
1.44
1.74
1.03
1.25
PS Ratio
0.38
1.23
--
5.47
1.56
0.55
0.56
0.90
0.93
0.90
2.59
1.80
1.70
1.32
1.48
3.63
5.98
PEG Ratio
1.47
1.28
1.10
1.24
0.69
0.59
1.26
1.50
1.58
1.31
1.46
2.10
1.39
1.16
1.46
0.74
0.94
EV-to-Revenue
8.19
10.17
8.21
8.34
4.69
3.58
7.19
9.51
9.52
8.67
10.16
11.98
8.50
6.56
8.97
5.68
7.31
EV-to-EBITDA
8.81
11.62
9.34
9.30
5.21
3.90
7.75
10.23
10.18
9.52
11.37
13.03
9.79
7.39
10.13
6.80
8.79
EV-to-EBIT
11.35
8.61
10.71
10.75
19.19
25.64
12.90
9.78
9.82
10.50
8.80
7.67
10.21
13.53
9.87
14.71
11.38
Earnings Yield (Joel Greenblatt) %
25.01
20.90
6.32
8.36
14.58
23.43
25.54
24.97
23.56
22.34
16.29
16.33
16.23
16.70
17.46
14.75
9.83
Forward Rate of Return (Yacktman) %
32.60
26.87
21.31
24.32
14.12
12.76
24.75
29.76
32.36
26.80
30.48
40.89
24.10
20.72
23.17
11.26
13.04
Shiller PE Ratio

Valuation and Quality

Dec07
Dec08
Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
TTM Fiscal Period
608
526
488
665
454
455
1,050
1,296
1,595
1,498
1,779
2,775
1,701
1,622
1,963
1,022
1,213
Market Cap
623
547
482
641
404
384
904
1,185
1,452
1,323
1,532
2,497
1,474
1,319
1,730
740
914
Enterprise Value
18.54
17.12
15.95
21.73
15.19
16.47
37.79
51.30
63.88
61.20
74.05
118
78.55
77.10
101
53.20
62.83
Month End Stock Price
-1.76
-2.52
-1.16
-1.12
-0.68
-0.40
1.37
-0.37
0.03
1.24
3.79
4.86
3.21
5.36
2.95
6.58
7.53
Net Cash per Share
-0.75
-1.24
0.09
0.71
1.19
1.84
4.36
2.79
4.08
5.41
7.66
9.72
7.58
10.74
9.41
11.57
12.73
Net Current Asset Value
-1.46
-2.06
-0.67
-0.48
-0.06
0.26
2.22
0.53
1.36
2.57
5.10
6.60
4.81
7.50
5.49
8.32
9.20
Net-Net Working Capital
15.29
17.49
18.98
20.39
25.26
30.18
36.96
45.67
52.19
60.80
68.65
75.65
82.82
86.17
91.31
82.16
76.33
Intrinsic Value: Projected FCF
22.60
19.74
21.02
24.16
27.91
32.56
35.71
40.14
48.17
55.52
58.50
69.83
71.47
84.22
95.21
84.48
82.59
Median PS Value
33.38
13.97
--
--
9.73
29.86
67.09
57.06
68.40
67.79
28.48
65.25
46.19
58.31
68.23
--
-- Peter Lynch Fair Value
5.49
4.21
7.40
9.60
11.81
15.08
21.22
20.67
26.98
31.71
27.13
40.92
37.40
49.66
48.03
40.22
40.06
Graham Number
19.87
23.23
25.32
26.43
32.44
39.69
49.33
60.33
66.86
79.07
86.49
94.74
110
123
134
142
141
Earnings Power Value (EPV)
11.65
8.48
11.64
11.22
8.19
7.96
10.02
10.75
11.04
10.44
10.95
14.84
10.47
8.89
10.74
7.46
8.43
Altman Z-Score
5.00
5.00
6.00
8.00
7.00
7.00
9.00
5.00
8.00
6.00
7.00
8.00
5.00
8.00
6.00
6.00
6.00
Piotroski F-Score
-2.81
-3.10
-2.76
-1.31
-2.96
-2.64
-2.26
-2.98
-2.65
-2.49
-3.32
-2.70
-2.93
-2.84
-2.53
-2.65
-2.78
Beneish M-Score
0.54
0.49
0.55
0.98
0.61
0.47
0.43
0.32
0.39
0.35
0.25
0.22
0.23
0.27
0.25
0.27
0.27
Scaled Net Operating Assets
12.93
-0.66
3.47
12.95
-3.58
-6.77
0.47
-3.50
1.97
-1.06
-9.31
7.77
-14.26
-0.28
1.64
-3.72
-2.94
Sloan Ratio %
1.14
0.97
1.28
1.39
1.78
1.87
2.39
1.76
1.86
2.01
2.41
2.64
2.42
2.53
2.27
2.67
3.04
Current Ratio
0.66
0.53
0.65
0.80
1.16
1.36
1.90
1.34
1.36
1.54
1.96
2.09
1.91
1.99
1.66
2.21
2.54
Quick Ratio
0.32
0.24
0.34
0.42
0.84
1.00
1.52
1.02
1.09
1.27
1.75
1.87
1.73
1.86
1.49
2.01
2.27
Cash Ratio
N/A
60.60
83.40
726
8,584
4,909
116,712
900
9,444
312
2,881
5,232
2,215
348
2,986
560
531
Interest Coverage
30.80
24.74
18.50
22.54
21.73
24.63
45.71
59.09
88.06
74.13
75.60
136
119
91.20
106
103
76.58
Highest Stock Price
14.74
9.32
9.30
12.32
11.80
15.46
16.44
28.81
48.97
47.41
54.25
70.75
58.92
45.78
77.95
48.66
48.61
Lowest Stock Price
8.21
6.35
0.27
--
2.41
7.49
-0.47
9.02
1.15
1.97
1.88
1.90
8.11
2.85
7.82
0.96
-0.57
Shares Buyback Ratio %
12.57
7.44
0.34
2.56
7.37
15.00
1.72
10.71
3.83
4.31
2.81
3.80
8.82
3.52
9.06
2.48
-- Buyback Yield %
26.11
7.92
6.68
14.68
15.08
16.34
16.31
14.21
20.70
15.26
5.52
13.86
-3.66
14.81
9.26
-11.33
-12.37
YoY Rev. per Sh. Growth
19.55
-29.66
17.30
31.80
13.99
36.50
24.94
0.72
28.21
11.14
-36.59
102
-13.87
32.88
-2.22
-37.35
-37.34
YoY EPS Growth
19.46
-24.66
14.11
26.89
14.48
30.22
23.04
2.92
27.20
5.16
0.25
38.57
-10.05
24.28
0.30
-28.88
-28.70
YoY EBITDA Growth
36.15
15.10
-0.03
2.78
5.97
13.39
24.09
20.27
19.08
16.99
11.32
12.77
10.45
9.95
11.95
4.08
3.10
5-Year EBITDA Growth Rate
33.47
32.10
30.68
31.06
30.72
29.09
27.39
26.44
25.46
24.19
24.35
24.11
22.64
21.16
20.15
19.25
19.28
Shares Outstanding (Basic Average)
32.78
30.70
30.62
30.62
29.88
27.64
27.77
25.27
24.98
24.49
24.02
23.57
21.66
21.04
19.39
19.21
19.30
Shares Outstanding (EOP)
0.06
0.16
0.79
0.85
1.25
0.88
1.27
2.22
1.00
1.08
0.02
0.64
0.48
0.96
1.07
0.77
0.34
Beta
03/13/08
03/06/09
03/17/10
03/14/11
03/14/12
03/11/13
03/13/14
03/17/15
03/01/16
03/01/17
02/28/18
02/26/19
02/25/20
03/02/21
03/01/22
02/28/23
  Filing Date
03/06/09
03/17/10
03/14/11
03/11/13
03/13/14
03/17/15
03/01/16
03/01/17
02/28/18
02/26/19
02/25/20
03/02/21
03/01/22
02/28/23
02/28/23
02/28/23
  Restated Filing Date
02/09/10
02/08/12
02/06/13
02/05/14
02/11/15
02/10/16
02/08/17
02/06/18
02/05/19
02/05/20
02/09/21
02/09/22
02/08/23
  Earnings Release Date
511
475
414
410
384
370
330
317
294
288
277
261
260
254
247
244
244
Number of Shareholders
956
948
--
--
1,290
1,330
1,480
--
--
1,788
1,810
1,911
1,909
--
--
1,900
1,900
Number of Employees
* All financial numbers are in millions except for per share data, ratios and percentage change.
GuruFocus Manual of Stocks™  |  Jun 06, 2023
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA

Business & Geographic Segmentation

Business Segments

Dec07
Dec08
Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
TTM Fiscal Period
--
--
--
--
--
--
--
--
--
--
--
--
--
--
1,186
995
995
Direct-selling
--
--
--
--
--
--
--
--
--
10.06
20.95
11.89
10.61
11.35
11.87
3.56
3.56
All Other
--
--
--
--
--
--
--
--
--
835
869
975
881
964
1,020
--
0.08
USANA Nutritionals
--
--
--
--
--
--
--
--
--
101
94.25
107
84.87
79.43
83.05
--
2.64
USANA Foods
--
--
--
--
--
--
--
--
--
--
--
--
84.87
79.43
71.19
--
-2.73
Personal care and Skincare
--
--
--
--
--
--
--
--
--
--
--
59.46
--
--
--
--
-- Celavive
--
--
--
--
--
--
--
--
--
60.37
62.84
35.68
--
--
--
--
-- Sense-beautiful science

Geographic Segments

Dec07
Dec08
Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
TTM Fiscal Period
--
--
--
--
--
--
--
--
--
217
483
587
471
470
506
453
-- China
--
--
--
--
--
--
--
--
--
111
116
116
104
220
223
197
-- Americas and Europe
--
--
--
--
--
--
--
--
--
206
205
225
220
270
270
190
-- Southeast Asia Pacific
--
--
--
--
--
--
--
--
--
46.02
58.38
76.72
96.19
115
130
109
-- North Asia
--
--
--
--
--
--
--
--
--
285
63.81
67.88
64.83
60.33
57.37
49.35
-- Greater China
--
--
--
--
--
--
--
--
--
140
121
116
105
--
--
--
-- United States
* All financial numbers are in millions except for per share data, ratios and percentage change.
GuruFocus Manual of Stocks™  |  Jun 06, 2023
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA

Explanation

1. Predictability Rank

GuruFocus Predictability Rank is a proprietary ranking of the consistency of a business. We rank the predictability of companies based on the consistency of their revenue per share and EBITDA (earnings before interest, tax, depreciation and amortization) per share over the past 10 fiscal years. Our study found that there is a strong correlation between the stock performance and the predictability of a business. Over the long term, companies with higher predictability also have better stock performance.

The rank is from 1-star to 5-star, with 5-star as the best.

2. Financial Strength

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

  1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
  2. Debt to revenue ratio. The lower, the better.
  3. Altman Z-Score.

The rank is from 1 to 10, with 10 as the highest.

A Financial Strength rank of 8 or above indicates good financial strength; between 4-7 indicates fair financial strength; 3 or below means poor financial strength.

3. Profitability Rank

GuruFocus Profitability Rank indicates how profitable a company is and how likely it is that the company's business will stay that way. It is based on these factors:

  1. Operating Margin %.
  2. Piotroski F-Score.
  3. Trend of the Operating Margin percentage (five-year average). A company with an uptrend in profit margin will have a higher rank.
  4. Consistency of the profitability.
  5. Predictability Rank.

The rank is from 1 to 10, with 10 as the highest.

A Profitability Rank of 8 or above indicates good profitability; between 4-7 indicates fair profitability; 3 or below means poor profitability.

4. Peter Lynch Chart

In Peter Lynch's excellent book, "One Up on Wall Street," he used many charts to illustrate the valuation of stocks. “A quick way to tell if a stock is overpriced is to compare the price line to the earnings line. If you bought familiar growth companies – such as Shoney’s, The Limited, or Marriott – when the stock price fell well below the earnings line, and sold them when the stock price rose dramatically above it, the chances are you’d do pretty well.”

The original Peter Lynch Chart does have limitations due to the right side price scale is pre-set at 15 times the earnings scale on the left side. When the stock price and earnings line coincide, the price-to-earnings ratio is always 15 times. Instead of using the fixed PE Ratio of 15, our approach is using 15-year historical median PE without NRI Ratio for each stock.

The Peter Lynch Chart with earnings line at median PE without NRI ratio works well for the companies with steady growth and earnings trends, or the stalwarts, as coined by Lynch. These companies tend to be found in sectors such as consumer staples, healthcare, and utilities, where the consumption of the product or service is relatively independent of economic conditions. It does not work well with the sectors that are cyclical: industrials, chemicals, durable goods, and so forth.

5. GF Value

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

  1. Possible Value Trap, Think Twice
  2. Significantly Overvalued
  3. Modestly Overvalued
  4. Fairly Valued
  5. Modestly Undervalued
  6. Significantly Undervalued
There is only a sufficient margin of safety when the stock is undervalued.

Disclaimer

GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.